John M. Maris

The paper develops a system to create binders compatible across HLA allotypes, validated against clinically relevant antigens and demonstrated in CAR T cells.

The paper identifies specific HLA class I and II alleles associated with increased risk of certain tumor types in NF1 patients using RNA-seq and DNA sequencing data.

This paper designs antibodies de novo with atomic precision using RFdiffusion and yeast display, validated by cryo-EM and biophysical methods.

This paper identifies and validates 5q31.1 as a neuroblastoma susceptibility locus in Chinese children through GWAS and functional studies.

This paper identifies DLK1 as a novel immunotherapeutic target in adrenocortical carcinoma, showing it regulates tumor cell plasticity and chemoresistance, and demonstrates the efficacy of a DLK1-targeting antibody-drug conjugate.

IMMUNOTAR prioritizes and identifies immunotherapeutic targets by integrating RNA-sequencing and proteomics data with public databases to evaluate surface proteins across diverse criteria.

This paper identifies cell state-dependent and -independent immunotherapeutic targets in neuroblastoma by analyzing subtype-specific gene expression and validating targets through experimental methods.

The paper introduces OpenPedCan, a harmonized multi-omic dataset of pediatric cancer patients, providing integrated genomic, transcriptomic, and proteomic data for research and clinical applications.

This study identifies DLK1 as a potential immunotherapeutic target in neuroblastoma through integrative proteomic, transcriptomic, and epigenomic analysis.

This paper describes a collaborative model between young investigators and cancer advocates to enhance pediatric cancer research through improved communication and team science.

This study shows BPTF works with MYCN and MYC to control cell cycle and epigenetic states in neuroblastoma, linking it to poor prognosis and therapeutic potential.

This study identifies BARD1 germline variants associated with reduced BARD1 expression and DNA repair defects in neuroblastoma, showing haploinsufficiency and increased genomic instability.

This study identifies 13.9% of neuroblastoma patients with pathogenic germline variants in cancer predisposition genes, associated with worse survival and enriched in DNA repair genes like BARD1.

annoFuse filters and prioritizes oncogenic gene fusions from RNA-Seq data, improving identification of clinically relevant fusions in cancer datasets.

This study identifies somatic structural variations in neuroblastoma, showing their enrichment in neurodevelopmental genes and the tumor suppressor role of SHANK2.

The paper provides ChIP-Seq and ATAC-Seq data for MYCN, MYC, and histone marks in neuroblastoma cell lines to study gene regulation and enhancer dynamics.

This paper genomically characterizes 261 pediatric cancer patient-derived xenograft models to guide rational clinical trial design and drug development.